Can You Administer Diltiazem ER 60 mg Twice Daily (12-Hour Formulation)?
No, you should not use diltiazem ER 60 mg twice daily as a 12-hour formulation without verifying the specific extended-release formulation type, as different ER preparations have distinct pharmacokinetic profiles and approved dosing intervals.
Critical Formulation Distinction
The FDA labeling distinguishes between immediate-release and extended-release diltiazem formulations, but does not specify a universal "12-hour ER" product 1. The key issue is that extended-release formulations vary significantly:
- Immediate-release diltiazem: Dosed 3-4 times daily (30-120 mg per dose), with a plasma half-life of 3.0-4.5 hours and peak levels at 2-4 hours 1
- Extended-release formulations: The FDA label references "ER" formulations with maintenance dosing of 120-360 mg daily for rate control, but does not specify BID vs QD dosing 2
Evidence on BID Extended-Release Dosing
Twice-daily controlled-release diltiazem formulations are clinically effective and well-studied:
- A controlled-release formulation dosed at 120-360 mg BID demonstrated effective rate control in hypertension with 24-hour blood pressure monitoring 3
- Diltiazem controlled-release BID was more effective than standard formulation in preventing myocardial ischemia at 12 hours post-dose in stable angina 4
- Studies confirm that 90 mg BID sustained-release formulations provide equivalent antihypertensive efficacy to once-daily dosing 5
Critical Caveats
However, once-daily formulations may be superior for compliance:
- Once-daily diltiazem CD (controlled delivery) was as effective as twice-daily SR (sustained release) for 24-hour blood pressure control and has the advantage of simplified dosing 6
- One study showed that maximum-dose diltiazem was less effective when given once daily versus twice daily, suggesting dose-dependent differences 7
Practical Recommendation
Before prescribing diltiazem ER 60 mg BID:
Verify the specific product formulation - Check whether you have:
- A sustained-release (SR) formulation designed for BID dosing
- A controlled-delivery (CD) formulation designed for QD dosing
- The product labeling should explicitly state the intended dosing interval
For rate control in atrial fibrillation (per ACC/AHA guidelines): The maintenance dose range is 120-360 mg daily (ER formulation), which could be administered as 60-180 mg BID if using an appropriate SR formulation 2
Starting dose considerations: 60 mg BID (120 mg total daily) falls within the therapeutic range, but immediate-release formulations typically start at 30 mg QID 1
Avoid in heart failure with reduced ejection fraction - Both diltiazem formulations are contraindicated in HFrEF 2
The safest approach: Use a formulation explicitly labeled for twice-daily dosing (SR formulation) if prescribing BID, or switch to a once-daily CD formulation at an equivalent total daily dose for improved compliance. Do not assume all "ER" products are interchangeable—pharmacokinetic profiles differ substantially between formulation types 1, 6.